Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 5/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.53 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | GPX4 | P36969 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12660615 | 0.93 | TRPV1 (0.55) | HDAC1HDAC6TRPV1BAZ2BKDR | |
| SCHEMBL12660612 | 0.93 | HDAC1 (0.53) | HDAC1HDAC6TRPV1BAZ2BKDR | |
| SCHEMBL12660620 | 0.86 | HDAC1 (0.51) | HDAC1HDAC6TRPV1KDRGPX4 | |
| SCHEMBL12831136 | 0.84 | TRPV1 (0.49) | HDAC1HDAC6TRPV1BAZ2BKDR | |
| SCHEMBL13627286 | 0.83 | HDAC6 (0.76) | HDAC1HDAC6TRPV1GPX4TAAR1 | |
| SCHEMBL12660616 | 0.82 | HDAC1 (0.46) | HDAC1HDAC6TRPV1KDRGPX4 | |
| SCHEMBL12831137 | 0.82 | HDAC1 (0.49) | HDAC1HDAC6TRPV1KDRGPX4 | |
| SCHEMBL8243500 | 0.80 | HDAC1 (0.71) | HDAC1HDAC6TRPV1BAZ2BKDR | |
| SCHEMBL8243868 | 0.76 | HDAC1 (0.62) | HDAC1HDAC6TRPV1GPX4ATM | |
| SCHEMBL8315964 | 0.76 | HDAC6 (0.65) | HDAC1HDAC6TRPV1GPX4TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133104-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2015-09-15 | — | — | US | disclosed |
| US-20140163042-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-12 | — | — | US | disclosed |
| US-20130116318-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116318-A1 | Enzyme Inhibitors | HDAC1, HDAC11, HDAC7 | HDAC1 1/4885HDAC6 11/4885TRPV1 4830/4885 |
| US-20140163042-A1 | ENZYME INHIBITORS | HAT1, NR2E1, HDAC3 | HDAC1 5/4885HDAC6 557/4885TRPV1 4811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.